Jocelyn Hudson

3 weeks ago | vascularspecialistonline.com | Jocelyn Hudson

Implantation Oof the VenoValve (enVVeno Medical) continues to promote stabilization of symptoms in patients with deep venous reflux at two-year follow-up. This is the headline finding of data shared yesterday during Plenary Session 6 at VAM 2025.

3 weeks ago | vascularspecialistonline.com | Jocelyn Hudson

Staged total endovascular aortic repair (TEAR) utilizing arch branched and thoracoabdominal fenestrated and branched endografts is effective, but identified predictors of morbidity and mortality—including stroke—highlight the importance of individualized risk assessment to optimize outcomes. These are some of the key findings of a study presented during yesterday’s Plenary Session 3.

3 weeks ago | vascularnews.com | Jocelyn Hudson

Sherene Shalhub (Oregon Health and Science University, Portland, USA) set out a new biologically informed framework that “captures the diverse spectrum of arterial fragility and repair outcomes across inherited and acquired aortic disease” during today’s Roy Greenberg Distinguished Lecture on Innovation at the 2025 Vascular Annual Meeting (VAM; 4–7 June, New Orleans, USA).

3 weeks ago | vascularspecialistonline.com | Jocelyn Hudson

The four-branch Gore Excluder thoracoabdominal branch endoprosthesis (TAMBE) device demonstrated low mortality at one year with renal artery occlusion being the predominant device-related event associated with small renal arteries and pararenal aneurysms. So concluded Mark A. Farber, MD, presenting the latest TAMBE data during yesterday’s William J. von Liebig Forum.

3 weeks ago | vascularnews.com | Jocelyn Hudson

Reflow Medical recently announced that the US Food and Drug Administration (FDA) has granted de novo clearance for the company’s Spur peripheral retrievable stent system, which is designed for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease.